Ashley Yeo is attached to the medtech titles within Informa’s Pharma intelligence division.
As Health Care editor on In Vivo (monthly hardcopy and online daily services), he writes and commissions news and feature material to meet the strategic business and market access information needs of senior players and device makers as they move innovations into the global medtech market place.
As part of the Principal Analyst team, he also contributes news delivery and insight needs across the group’s other medtech titles in the field of market access (global regulatory, reimbursement, policy changes). Key areas of focus are Germany, the UK and global themes, and EU and other outside global regulatory insight.
A linguist by training, he joined what was later to become Informa in mid-1988 as a French and German news reporter (with some other European languages also in the mix), and has been editor of three of the group’s titles (including Clinica) over a 14-year-period.
These duties are combined with supporting the growing Ask The Analyst service. He says: “This helps us as a group keep a close relationship with long-term and potential subscribers in a sector where insight and knowledge are key to our clients’ commercial success.”
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ashley Yeo
Integra LifeSciences surged to industry-leading 12% sales growth in 2016, and that's before it prepares to consolidate two of the biggest acquisitions in its history. What is the strategy behind the success of the specialty surgery, orthopedics and tissue tech company that is looking at another double-digit sales uplift in 2017?
It's been a big month for plans intended to shape the future of health care in the US, with the Trump Administration showcasing its ACA replacement bill and issuing budget proposals. At this stage, it's hard to peg winners and losers and although the focus is squarely on insurance, the medtech sector should guard against complacency, says ZS Associates' Brian Chapman.
Progress on ratifying the ASEAN Medical Device Directive (AMDD) continues apace, with some of the Association of Southeast Asian Nations members surging ahead. Malaysia and Vietnam, in particular, are making big efforts to build or strengthen their national regulatory systems foe devices. Also, non-ASEAN state India is taking real steps in a similar direction, say Asia Regulatory Professional Association (ARPA) secretary Jack Wong and ARQon consultant May Ng in this latest Asian regulatory update.
Addressing pricing challenges for implantable devices, responding to a national localization drive and working with the Russian health-care products regulator Roszdravnadzor on market access issues for international companies are high priorities for IMEDA, Russia's International Medical Device Manufacturers Association. But, increasingly, another major focus is ensuring the stability of the local industry.
Free: In Vivo's Ashley Yeo talks to Association of British Healthcare Industries' Nishan Sunthares and Richard Phillips about the subject that will dominate the thoughts, behavior and business of medical technology companies in the UK for many years to come.
The era of integrated health care has arrived, at least as far as the European medical technology industry is concerned, where the devices and IVDs industry associations have merged under the umbrella name MedTech Europe. MTE chairman Rob ten Hoedt explains what this means in practice.